Creatinine-based non-phospholipid vesicular carrier for improved oral bioavailability of Azithromycin

References

• Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery – a review. Pharm Sci Technol Today 2000;3:138–45.
   PubMedGoogle Scholar
• Hu M, Li X. Barriers to oral bioavailability – an overview. NJ, USA: John Wiley & Sons; 2011.
   Google Scholar
• Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007;12:1068–75.
   PubMed Web of Science ®Google Scholar
• Huang L-F, Tong W-QT. Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev 2004;56:321–34.
   PubMed Web of Science ®Google Scholar
• Kawabata Y, Wada K, Nakatani M, et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm 2011;420:1–10.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang S, Zhang M, Sun J. Nanocarriers for oral drug delivery. J Drug Target 2013;21:515–27.
   PubMed Web of Science ®Google Scholar
• Cai Z, Wang Y, Zhu L-J, Liu Z-Q. Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab 2010;11:197–207.
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001;47:55–64.
   PubMed Web of Science ®Google Scholar
• Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm Sin B 2011;1:208–19.
   Web of Science ®Google Scholar
• Uchegbu IF, Double JA, Turton JA, Florence AT. Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Pharm Res 1995;12:1019–24.
   PubMed Web of Science ®Google Scholar
• Hasan AA, Madkor H, Wageh S. Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system. Drug Deliv 2013;20:120–6.
   PubMed Web of Science ®Google Scholar
• Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci 2010;99:2049–60.
   PubMed Web of Science ®Google Scholar
• Jain S, Vyas S. Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J Liposome Res 2006;16:331–45.
   PubMed Web of Science ®Google Scholar
• Roger E, Lagarce F, Garcion E, Benoit J-P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine 2010;5:287–306.
   PubMed Web of Science ®Google Scholar
• Duan X, Li Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small 2013;9:1521–32.
   PubMed Web of Science ®Google Scholar
• Cosco D, Paolino D, Muzzalupo R, et al. Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil. Biomed Microdev 2009;11:1115–25.
   PubMed Web of Science ®Google Scholar
• Söderlind E, Wollbratt M, von Corswant C. The usefulness of sugar surfactants as solubilizing agents in parenteral formulations. Int J Pharm 2003;252:61–71.
   PubMed Web of Science ®Google Scholar
• Aramaki K, Yamada J, Tsukijima Y, et al. Formation of bilayer membrane and niosomes by double-tailed polyglyceryl-type nonionic surfactant. Langmuir 2015;31:10664–71.
   PubMed Web of Science ®Google Scholar
• Ramsh S, Zheltonog N, Khrabrova E, Golovanova E. Hydroxy- and aminomethylation of 1-methyl-2-amino-4-imidazolinone. Chem Heterocycl Compd 1991;27:601–3.
   Google Scholar
• Lempert C. The chemistry of the glycocyamidines. Chem Rev 1959;59:667–736.
   Web of Science ®Google Scholar
• Khan SN, Shoaib M, Shah SWA, et al. Pharmacological activities and one pot two step synthesis of novel (E)-N-(1-methyl-4-oxoimidazolidin-2-ylidene) benzamide. World J Zool 2015;10:241–6.
   Google Scholar
• Cade J. The anticonvulsant properties of creatinine. Med J Aust 1947;2:621.
   PubMedGoogle Scholar
• Pfeifer A, Pataky I, Hajdu P. A contribution to the effects of creatinine on the central nervous system. II. Anticonvulsant action. Acta Physiol Hung 1952;3:153.
   PubMedGoogle Scholar
• Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010;28:436–40.
   PubMed Web of Science ®Google Scholar
• Waikar SS, Betensky RA, Bonventre JV. Creatinine as the gold standard for kidney injury biomarker studies? Nephrol Dial Transplant 2009;24:3263–5.
   PubMed Web of Science ®Google Scholar
• Jones JD, Burnett PC. Implication of creatinine and gut flora in the uremic syndrome: induction of ‘creatininase’ in colon contents of the rat by dietary creatinine. Clin Chem 1972;18:280–4.
   PubMed Web of Science ®Google Scholar
• Zhong M, Feng Y, Liao H, et al. Azithromycin cationic non-lecithoid nano/microparticles improve bioavailability and targeting efficiency. Pharm Res 2014;31:2857–67.
   PubMed Web of Science ®Google Scholar
• Zhang D, Tan T, Gao L, et al. Preparation of Azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm 2007;33:569–75.
   PubMed Web of Science ®Google Scholar
• Imran M, Shah MR, Ullah F, et al. Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime. Int J Pharm 2016;505:122–32.
   PubMed Web of Science ®Google Scholar
• Ullah S, Shah MR, Shoaib M, et al. Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. Drug Deliv 2016;23:3480–91.
   PubMed Web of Science ®Google Scholar
• Cenni E, Granchi D, Avnet S, et al. Biocompatibility of poly (d, l-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials 2008;29:1400–11.
   PubMed Web of Science ®Google Scholar
• Akuodor G, Usman MI, Ibrahim J, et al. Anti-nociceptive, anti-inflammatory and antipyretic effects of the methanolic extract of Bombax buonopozense leaves in rats and mice. Afr J Biotechnol 2013;10:3191–6.
   Google Scholar
• Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992;81:309–12.
   Web of Science ®Google Scholar
• Essa E. Effect of formulation and processing variables on the particle size of sorbitan monopalmitate niosomes. Asian J Pharm 2010;4:227.
   Google Scholar
• Shi B, Fang C, Pei Y. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci 2006;95:1873–87.
   PubMed Web of Science ®Google Scholar
• Tavano L, Aiello R, Ioele G, et al. Niosomes from glucuronic acid-based surfactant as new carriers for cancer therapy: preparation, characterization and biological properties. Colloids Surf B Biointerfaces 2014;118:7–13.
   PubMed Web of Science ®Google Scholar
• Waddad AY, Abbad S, Yu F, et al. Formulation, characterization and pharmacokinetics of Morin hydrate niosomes prepared from various non-ionic surfactants. Int J Pharm 2013;456:446–58.
   PubMed Web of Science ®Google Scholar
• Sahoo RK, Biswa N, Guha A, et al. Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectives. BioMed Res Int 2014;2014:263604. doi: 10.1155/2014/263604
   PubMed Web of Science ®Google Scholar
• Kong M, Park H, Feng C, et al. Construction of hyaluronic acid noisome as functional transdermal nanocarrier for tumor therapy. Carbohydr Polym 2013;94:634–41.
   PubMed Web of Science ®Google Scholar
• Valdés K, Morilla MJ, Romero E, Chávez J. Physicochemical characterization and cytotoxic studies of nonionic surfactant vesicles using sucrose esters as oral delivery systems. Colloids Surf B Biointerfaces 2014;117:1–6.
   PubMed Web of Science ®Google Scholar
• Kissa E. Fluorinated surfactants and repellents. Florida, USA: CRC Press; 2001:97.
   Google Scholar
• Tavano L, Vivacqua M, Carito V, et al. Doxorubicin loaded magneto-niosomes for targeted drug delivery. Colloids Surf B Biointerfaces 2013;102:803–7.
   PubMed Web of Science ®Google Scholar
• Tao L, Uhrich KE. Novel amphiphilic macromolecules and their in vitro characterization as stabilized micellar drug delivery systems. J Colloid Interface Sci 2006;298:102–10.
   PubMed Web of Science ®Google Scholar
• Akhter S, Kushwaha S, Warsi MH, et al. Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir. Drug Dev Ind Pharm 2012;38:84–92.
   PubMed Web of Science ®Google Scholar
• Arzani G, Haeri A, Daeihamed M, et al. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomed 2015;10:4797.
   PubMed Web of Science ®Google Scholar
• Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004;21:201–30.
   PubMed Web of Science ®Google Scholar
• Attia IA, El-Gizawy SA, Fouda MA, Donia AM. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. AAPS PharmSciTech 2007;8:206–12.
   Web of Science ®Google Scholar